A fund with a focus.

The Mii Fund looks at skin innovation in a broad and holistic manner from pharma to digital, from med-tech to microbiome and cosmetics, from market need to market impact.

Vision:

To create a synergy between the best of Israeli life-science innovation and Japanese corporate culture and big pharma expertise.

Japan First:

Through the fund’s partnership with Maruho,
Japan’s preeminent leader in dermatology, the Mii Fund aims to bring Israeli innovation in dermatology and skin care to the Japanese market, in effect giving Japan first rights to next generation skin therapies.

Me & You

Mii is seeking innovative skin-related technologies across all stages and categories with significant market impact potential.

MII invests in dermatology related technologies across different stages seed to growth – covering the pharma, biotech, medical device, digital health, and cosmetic sectors.

Mii Team
Eran Perry,
Co-Founder &
Managing Director

For the past 15 years Eran has been intricately involved in healthcare innovation, both as an entrepreneur and as a venture capital investor.

Eran is deeply rooted in the Israeli life-science ecosystem as a co-founder and board member of several pharmaceutical companies including ICD Pharma, Musli Thyropeutics, Seanergy Dermatology, Follicle Pharma, and others. He serves as the Chairman of the Investment Committee.

Formerly, Eran served as a Managing Director and Partner of Israel Healthcare Ventures (IHCV), a healthcare focused venture capital group, as a consultant in McKinsey & Company, serving clients worldwide in the Pharmaceutical, Telecom, and Government sectors, and as a member of the Global Marketing group at Novartis Oncology in New Jersey, USA.

Before moving to private sector, Eran served in the Israeli Ministry of Justice, as a Senior Advisor to the Director General of the Ministry.

Education:
Eran holds an MBA from Columbia University, an LL.B. in Law from Tel Aviv University, and a B.Sc. in Mathematics and Computer Science from Tel Aviv University.

READ MORE

Dr. Doron Friedman,
Co-Founder &
Managing Director

With more than 80 patents, many of them in the field of drug delivery systems, Doron is one of the most active pharma inventors around. His innovations are behind drugs selling under some of the world’s leading brands — products such as Lotemax™, Scytera™, Finacea™ and others. In MII Doron is an investor and inventor. He is one of the founders of MII, and the inventor behind a couple of its portfolio companies.
With a PhD in pharmaceutical sciences from the School of Pharmacy at the Hebrew University in Jerusalem, Doron has published over twenty peer-reviewed papers and over seventy patents in the field of drug delivery systems. Doron is the proud inventor of Lotemax™, Scytera™ and Finacea™ among others. He has also served as CTO at Pharmos Corp., and was a co-founder of Foamix Ltd (NASDAQ FOAMX), and ICDPharma Ltd.

Dr. Friedman is a co-founder of Foamix (NASDAQ FOAMX), ICD Pharma, Seanergy Dermatology and Foillcle Pharma. Formerly he has served as VP R&D of Lipocure and has led R&D in several other companies. Doron was a research associate at the liposomes and membrane laboratory at the Hebrew University of Jerusalem and a lecturer at the School of Engineering at the Hebrew University of Jerusalem. He held a post doctoral position at the School of Pharmacy Ann-Arbor, Michigan in Prof Gordon Amidon’s laboratories.

Education:

Doron holds a Ph.D. in Pharmaceutical Sciences from the Hebrew University Jerusalem.

READ MORE

Junichi Hamada,
Co-Founder &
Managing Director

As Maruho’s Head of Global Strategy, Junichi has led the company’s global business strategy ever since 2009.
He has played a key role in the company’s entrance into the Israeli innovation ecosystem. He is a member of Mii’s Investing Committee.

Junichi has served on the Board of Directors for Maruho’s subsidiaries in Europe and the US, and has served as Managing Director of Maruho Deutschland GmbH. He has overseen the restructuring of Maruho’s global business, including the sale of Maruho subsidiary Cutanea Life Sciences, Inc., to Biofrontera AG. Mr. Hamada was previously in charge of the Corporate Planning Department at Maruho, and prior to that was the CEO of Yatsude Co., Ltd., a pharmacy chain which was bought out by Maruho.

Education:

Junichi holds an MBA from the Arthur D. Little School of Management in Boston, Massachusetts, and B.A. in Pharmacy from Nihon University.

READ MORE

Masanobu Ogawa,
Co-Founder &
Managing Director

Masa’s passion is the innovation-driven evolution of Japan’s economy. He has  led a series of initiatives aimed to create a strategic bridge between Israel and Japan, one of them is the creation of MII Fund & Labs.

Masa, a Harvard-educated, McKinsey-experienced strategic consultant, has been supporting as many as 200 corporations both Japanese and global, in a variety of aspects – marketing, strategy, R&D, new business development, turn-around, alliances, M&A, and strategic resource allocation of conglomerates.  He has served clients across all sectors including healthcare, manufacturing, services, logistics and more.

Masa is an expert in the evolution of strategic thinking of both individuals and organizations and has authored several books this issue.

Formerly, Masa has served on the legal and policy making staff in the Government of Japan, Ministry of Agriculture, Forestry and Fisheries.  He is a Board member of Business Model Academy and a  Director of the Japan Israel Chamber of Commerce.


Education:
Masa holds an MBA from Harvard University, and BA in international economics, law, and relations from the University of Tokyo.

READ MORE

Mr. Kenichi Owada
Member of Investment Committee

Kenichi is an investment committee member of MII Fund and a managing director of Maruho Deutschland GmbH, Leverkusen, Germany which is subsidiary of Maruho Co., Ltd.

He has been working in finance & accounting area for the past 20 years. Formerly, Kenichi served as finance manager of Maruho Co., Ltd, Osaka, Japan for six years and was in charge of finance works like funding, M&A, investments, rating acquisition etc. He also worked for a chemical manufacturing company for over 10 years in Japan and the US.

Kenichi holds an MBA from University of Michigan business school, USA and a B.A. in Social Science from Waseda University, Japan.

READ MORE

Dr. Alona Weiss
Senior Analyst

Alona is a medical technology analyst with 20-year experience in investments, in-depth analysis of medical device and pharmaceutical technologies, Innovation, Business Development and Strategy.

Formerly, Alona held the position of Director Healthcare Investments at Elron Electronic industries Ltd. (TASE:ELRAN), a leading Israel-based technology holding company.  Prior to that Alona was a Managing Director at Israel Healthcare Ventures (IHCV), a fund specializing in healthcare investments where she headed the deal flow of the fund. Before that she served as Chief Operation Officer at ProSeed Biotech Services, Inc., a Boston based consulting firm, and as a Biotechnology Research Manager and ProSeed Capital Holdings CVA., Boston, MA.

In addition, Alona served as a Senior Licensing Officer at Yeda Research and Development Ltd. – the technology transfer arm of the Weizmann Institute of Science.

Alona was a Research Fellow at Harvard Medical School and at Massachusetts General Hospital.

Alona earned a Ph.D. degree in life science from the Hebrew University, M.Sc. degree from the Weizmann Institute of Science and B.Sc. from the Hebrew University.

READ MORE

Limor Regev Yuzik
CFO

Limor’s extensive experience in financial and accounting matters gives her a unique perspective on the financial management of corporations and funds.

Formerly, Limor held a position as a controller at Viola Group, a leading technology focused investment group, where she was responsible on the holding companies in all financial aspects including accounting, reporting, taxation, budgeting and cash flow.

Prior to that Limor held the position of the controller of Viola Partners, an exclusive investment fund tailored especially for private investors, family offices and foundations.

In addition, Limor served as a financial audit manager at BDO, in companies that worked both in the United States and in the Israeli accounting standards.

Limor holds a B.A. in Economic and Accounting from the Hebrew University of Jerusalem and is registered as a Certified Public Accountant (CPA) in Israel.

READ MORE
Eran Perry,
Co-Founder &
Managing Director

For the past 15 years Eran has been intricately involved in healthcare innovation, both as an entrepreneur and as a venture capital investor.

Eran is deeply rooted in the Israeli life-science ecosystem as a co-founder and board member of several pharmaceutical companies including ICD Pharma, Musli Thyropeutics, Seanergy Dermatology, Follicle Pharma, and others. He serves as the Chairman of the Investment Committee.

Formerly, Eran served as a Managing Director and Partner of Israel Healthcare Ventures (IHCV), a healthcare focused venture capital group, as a consultant in McKinsey & Company, serving clients worldwide in the Pharmaceutical, Telecom, and Government sectors, and as a member of the Global Marketing group at Novartis Oncology in New Jersey, USA.

Before moving to private sector, Eran served in the Israeli Ministry of Justice, as a Senior Advisor to the Director General of the Ministry.

Education:
Eran holds an MBA from Columbia University, an LL.B. in Law from Tel Aviv University, and a B.Sc. in Mathematics and Computer Science from Tel Aviv University.

READ MORE

Dr. Doron Friedman,
Co-Founder &
Managing Director

With more than 80 patents, many of them in the field of drug delivery systems, Doron is one of the most active pharma inventors around. His innovations are behind drugs selling under some of the world’s leading brands — products such as Lotemax™, Scytera™, Finacea™ and others. In MII Doron is an investor and inventor. He is one of the founders of MII, and the inventor behind a couple of its portfolio companies.
With a PhD in pharmaceutical sciences from the School of Pharmacy at the Hebrew University in Jerusalem, Doron has published over twenty peer-reviewed papers and over seventy patents in the field of drug delivery systems. Doron is the proud inventor of Lotemax™, Scytera™ and Finacea™ among others. He has also served as CTO at Pharmos Corp., and was a co-founder of Foamix Ltd (NASDAQ FOAMX), and ICDPharma Ltd.

Dr. Friedman is a co-founder of Foamix (NASDAQ FOAMX), ICD Pharma, Seanergy Dermatology and Foillcle Pharma. Formerly he has served as VP R&D of Lipocure and has led R&D in several other companies. Doron was a research associate at the liposomes and membrane laboratory at the Hebrew University of Jerusalem and a lecturer at the School of Engineering at the Hebrew University of Jerusalem. He held a post doctoral position at the School of Pharmacy Ann-Arbor, Michigan in Prof Gordon Amidon’s laboratories.

Education:

Doron holds a Ph.D. in Pharmaceutical Sciences from the Hebrew University Jerusalem.

READ MORE

Junichi Hamada,
Co-Founder &
Managing Director

As Maruho’s Head of Global Strategy, Junichi has led the company’s global business strategy ever since 2009.
He has played a key role in the company’s entrance into the Israeli innovation ecosystem. He is a member of Mii’s Investing Committee.

Junichi has served on the Board of Directors for Maruho’s subsidiaries in Europe and the US, and has served as Managing Director of Maruho Deutschland GmbH. He has overseen the restructuring of Maruho’s global business, including the sale of Maruho subsidiary Cutanea Life Sciences, Inc., to Biofrontera AG. Mr. Hamada was previously in charge of the Corporate Planning Department at Maruho, and prior to that was the CEO of Yatsude Co., Ltd., a pharmacy chain which was bought out by Maruho.

Education:

Junichi holds an MBA from the Arthur D. Little School of Management in Boston, Massachusetts, and B.A. in Pharmacy from Nihon University.

READ MORE

Masanobu Ogawa,
Co-Founder &
Managing Director

Masa’s passion is the innovation-driven evolution of Japan’s economy. He has  led a series of initiatives aimed to create a strategic bridge between Israel and Japan, one of them is the creation of MII Fund & Labs.

Masa, a Harvard-educated, McKinsey-experienced strategic consultant, has been supporting as many as 200 corporations both Japanese and global, in a variety of aspects – marketing, strategy, R&D, new business development, turn-around, alliances, M&A, and strategic resource allocation of conglomerates.  He has served clients across all sectors including healthcare, manufacturing, services, logistics and more.

Masa is an expert in the evolution of strategic thinking of both individuals and organizations and has authored several books this issue.

Formerly, Masa has served on the legal and policy making staff in the Government of Japan, Ministry of Agriculture, Forestry and Fisheries.  He is a Board member of Business Model Academy and a  Director of the Japan Israel Chamber of Commerce.


Education:
Masa holds an MBA from Harvard University, and BA in international economics, law, and relations from the University of Tokyo.

READ MORE

Mr. Kenichi Owada
Member of Investment Committee

Kenichi is an investment committee member of MII Fund and a managing director of Maruho Deutschland GmbH, Leverkusen, Germany which is subsidiary of Maruho Co., Ltd.

He has been working in finance & accounting area for the past 20 years. Formerly, Kenichi served as finance manager of Maruho Co., Ltd, Osaka, Japan for six years and was in charge of finance works like funding, M&A, investments, rating acquisition etc. He also worked for a chemical manufacturing company for over 10 years in Japan and the US.

Kenichi holds an MBA from University of Michigan business school, USA and a B.A. in Social Science from Waseda University, Japan.

READ MORE

Dr. Alona Weiss
Senior Analyst

Alona is a medical technology analyst with 20-year experience in investments, in-depth analysis of medical device and pharmaceutical technologies, Innovation, Business Development and Strategy.

Formerly, Alona held the position of Director Healthcare Investments at Elron Electronic industries Ltd. (TASE:ELRAN), a leading Israel-based technology holding company.  Prior to that Alona was a Managing Director at Israel Healthcare Ventures (IHCV), a fund specializing in healthcare investments where she headed the deal flow of the fund. Before that she served as Chief Operation Officer at ProSeed Biotech Services, Inc., a Boston based consulting firm, and as a Biotechnology Research Manager and ProSeed Capital Holdings CVA., Boston, MA.

In addition, Alona served as a Senior Licensing Officer at Yeda Research and Development Ltd. – the technology transfer arm of the Weizmann Institute of Science.

Alona was a Research Fellow at Harvard Medical School and at Massachusetts General Hospital.

Alona earned a Ph.D. degree in life science from the Hebrew University, M.Sc. degree from the Weizmann Institute of Science and B.Sc. from the Hebrew University.

READ MORE

Limor Regev Yuzik
CFO

Limor’s extensive experience in financial and accounting matters gives her a unique perspective on the financial management of corporations and funds.

Formerly, Limor held a position as a controller at Viola Group, a leading technology focused investment group, where she was responsible on the holding companies in all financial aspects including accounting, reporting, taxation, budgeting and cash flow.

Prior to that Limor held the position of the controller of Viola Partners, an exclusive investment fund tailored especially for private investors, family offices and foundations.

In addition, Limor served as a financial audit manager at BDO, in companies that worked both in the United States and in the Israeli accounting standards.

Limor holds a B.A. in Economic and Accounting from the Hebrew University of Jerusalem and is registered as a Certified Public Accountant (CPA) in Israel.

READ MORE